Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding

Abstract excerpt

Direct-acting antivirals (DAAs) have significantly improved the treatment of infection with the hepatitis C virus. A promising class of novel antiviral agents targets the HCV NS5A protein. The high potency and broad genotypic coverage are favorable properties. NS5A inhibitors are currently assessed in advanced clinical trials in combination with viral polymerase inhibitors and/or viral protease inhibitors....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hepatitis B Virus Studies
• Share to Hepatitis C virus research
• Share to Liver Disease Diagnosis and Treatment